Evidence map›Paper›PMID 42664350›Full record

ArticleScience advances2026

LATS1/2 inactivation drives a distinct venous endothelial cell response that contributes to fibrotic remodeling of the lung.

Konstantinos Kontodimas, Ahmed A Raslan, Benjamin Spira, Crystal Zhu, Janardhan Karapurkar, Yohana Kefella, Darren Chiu, Xintao Qiu, Jennifer E Beane, Giovanni Ligresti and 1 more

Abstract read
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Konstantinos KontodimasDepartment of Biochemistry and Cell Biology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.ORCID 0000-0001-9593-505X
Ahmed A RaslanPulmonary Center, Boston University, Boston, MA, USA.ORCID 0000-0003-4936-1459
Benjamin SpiraDepartment of Biochemistry and Cell Biology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.ORCID 0009-0004-6032-3335
Crystal ZhuDepartment of Biochemistry and Cell Biology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.ORCID 0009-0008-7131-3377
Janardhan KarapurkarPulmonary Center, Boston University, Boston, MA, USA.ORCID 0000-0002-0198-4035
Yohana KefellaDepartment of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.ORCID 0009-0009-8628-8343
Darren ChiuDepartment of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.ORCID 0000-0002-0183-6139
Xintao QiuDepartment of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.ORCID 0000-0002-8560-7017
Jennifer E BeaneDepartment of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.ORCID 0000-0002-6699-2132
Giovanni LigrestiPulmonary Center, Boston University, Boston, MA, USA.ORCID 0000-0002-3375-8665
Xaralabos VarelasDepartment of Biochemistry and Cell Biology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.ORCID 0000-0002-2882-4541

Funding

The Lung PCA: A Multi-Dimensional Atlas of Pulmonary PremalignancyU2CCA233238 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI DUBINETT, STEVEN M., SPIRA, AVRUM E · 2018 to 2021
$7.0M
The Boston University - UCLA Lung Cancer Biomarker Characterization CenterU2CCA271898 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MICHAEL J PALAZZOLO · 2022 to 2026
$5.5M
Defining epithelial polarity cues that direct cell fateR01HL124392 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI VARELAS, XARALABOS · 2014 to 2024
$4.5M
Epigenetic regulation of pulmonary fibrosisR01HL142596 · NHLBI · MAYO CLINIC ROCHESTER · PI Giovanni Ligresti · 2018 to 2026
$2.9M
Targeting vascular dysfunction to promote lung repair and fibrosis resolutionR01HL158733 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI LIGRESTI, GIOVANNI · 2022 to 2025
$2.8M
NCI NIH HHS U2C CA233238NCI NIH HHS U2C CA271898NHLBI NIH HHS R01 HL124392NHLBI NIH HHS R01 HL142596NHLBI NIH HHS R01 HL158733
6 · The paper itself

Abstract

Endothelial dysfunction is recognized to contribute to chronic tissue remodeling in the lung, yet endothelial-derived mechanisms driving these processes remain largely undefined. Here, we show that endothelial inactivation of the LATS1 and LATS2 kinases, key suppressors of the transcriptional regulators YAP and TAZ, elicits distinct responses depending on endothelial identity within different pulmonary vascular beds. Our data indicate that LATS1/2 inactivation in general capillary endothelial cells induces a reactive capillary injury-like state, whereas a separate endothelial population located within veins adopts a distinct profibrotic state. We show that expansion of this reactive venous endothelial cell population, which is marked by EBF1 and ACKR1 expression, is associated with fibroblast activation, macrophage accumulation, and epithelial remodeling, collectively generating a microenvironment characteristic of fibrotic lung disease. We further demonstrate that pharmacologic inhibition of YAP/TAZ-TEAD signaling prevents stromal and immune remodeling and fibrotic lesion formation following endothelial LATS1/2 inactivation. These findings identify LATS1/2-mediated restraint of YAP/TAZ as essential for lung endothelial homeostasis and highlight a distinct venous cell response as a direct contributor to fibrotic lung remodeling.

Indexed as

Endothelial CellsLungProtein Serine-Threonine KinasesPulmonary FibrosisTumor Suppressor ProteinsAnimalsFibroblastsHumansMiceSignal TransductionTrans-ActivatorsTranscription FactorsYAP-Signaling ProteinsLats1 protein, mouseLATS2 protein, humanLATS2 protein, mouseProtein Serine-Threonine KinasesTrans-ActivatorsTranscription FactorsTumor Suppressor ProteinsYAP-Signaling Proteins

Identifiers

PMID42664350
PMCPMC13524055

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.